Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAL ER for Cough in IPF
NCT05964335Phase 2Completed
- Sponsor
- Trevi Therapeutics
- Start
- Feb 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of nalbuphine in chronic cough, sponsored by Trevi Therapeutics. Started Feb 2024; status: completed.
02
Drugs
nalbuphine
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT05964335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05964335.